You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?



Discover the limitations of AVD treatment for SHPT in ND-CKD

15 September 2021

Meta-analysis highlights safety issues of treating SHPT in ND-CKD patients using AVD therapy1

According to a systematic review and meta-analysis by Cozzolino* et al. (2021), active vitamin D (AVD) analogues may not be optimal treatments for secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (ND-CKD).1

Summary of AVD systematic review and meta-analysis

A summary of the findings made by Cozzolino and team is provided below.


Share the infographic



Key takeaways

  • Cozzolino et al. confirmed the increased risk of hypercalcaemia with AVD analogue treatment (versus placebo) in patients with ND-CKD and elevated parathyroid hormone (PTH)1
  • This highlights an urgent unmet need for new therapies for patients with ND-CKD and SHPT

To read the full publication, visit the Clinical Kidney Journal website.

A detailed summary of the meta-analysis, as well as other studies that highlight unmet needs in the treatment of SHPT, can be found in a review article at the European Medical Journal website.

Footnotes and references

*Renal Division and Laboratory of Experimental Nephrology, Department of Health Sciences, University of Milan, Milan, Italy.

  1. Cozzolino M et al. Clin Kidney J 2021;14(11):2437–43.